Last reviewed · How we verify
GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL
To evaluate the safety and tolerability of GB5005 in patients with CD19-positive relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL).
Details
| Lead sponsor | The First Affiliated Hospital of Xiamen University |
|---|---|
| Phase | PHASE1 |
| Status | RECRUITING |
| Enrolment | 45 |
| Start date | Thu Apr 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon May 31 2027 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Non-hodgkin Lymphoma
- Refractory Lymphoma
- Chimeric Antigen Receptor T-cell
Interventions
- GB5005 CART
Countries
China